Search

Paige Arnold, who will graduate from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) next spring, has been awarded the 2022 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus Louis V. Gerstner, Jr., for whom the school is named.

A new drug delivery method could improve treatment of a lethal pediatric brain tumor called diffuse intrinsic pontine glioma.

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease, indicating that cancer diagnostics need to go beyond the analysis of DNA mutations.

Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal surgical cytoreduction.

On June 7 when Memorial Sloan Kettering opened a facility housing the novel Center for Image-Guided Interventions, a suite of endoscopy rooms, and new operating rooms for the Surgical Day Hospital.

Lonny Yarmus, DO, MBA, has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Dr. Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.